Results 181 to 190 of about 7,117 (221)

Pulmonary Coccidioidomycosis Occurring in a Patient Treated With Acalabrutinib for Chronic Lymphocytic Leukemia

Cureus
Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) approved for use in the treatment of chronic lymphocytic leukemia (CLL). Herein, we present a patient successfully treated with reduced-dose acalabrutinib for CLL, with pre-existing ...
Zahra Gafarzadeh, Cyril Gaultier, S. Salmasi, Ruba Alchaikh Hassan, Constantin A Dasanu   +4 more
semanticscholar   +1 more source

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal of Medical Economics
BACKGROUND AND AIM Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
George Dranitsaris, A. Peevyhouse, H. Neuhalfen, Lee Ann Dietz, C. Huynh, S. Wahlstrom, Samantha L. Thompson, A. Teschemaker, Vikram Shetty, M. Narkhede, Daniel Ermann, S. Blau   +11 more
semanticscholar   +1 more source

Comparative neuropsychiatric outcomes of ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia: A propensity-matched real-world cohort study

Blood
Background: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL). However, emerging evidence suggests that ibrutinib, a first-generation BTK inhibitor, may be associated with ...
Kirti Arora, Yuvraj Kaushal, Moath Albliwi, Aditi Arora, Manzer Ali, Kashish Magnani, Preksha Singh, S. Arora, Alec Ingros, R. Chowdhary, Laurie Matt-Amaral   +10 more
semanticscholar   +1 more source

A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)

Blood
Background and Significance Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy for which more effective therapeutic approaches are needed, particularly in patients who are ineligible for intensive regimens.
Ana Marín Niebla, A. M. Martin Garcia-Sancho, Jorge Castro García, Esther Álvarez García, Ángel Callejo Mellén, J. Sancho   +5 more
semanticscholar   +1 more source

A chemotherapy‐free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma

British Journal of Haematology
acalabrutinib–rituximab resulted in a 94% ORR and 90% CMR, with a 2-year PFS of 92% (28% had high-risk genetics). 3 Similarly, the combination of acalabrutinib, veneto-clax and rituximab showed a 100% ORR (71% CMRR) and a 2-year PFS of 63%, although data
P. Lopedote, G. Shouse, Sandrine Puverel, A. Muir, Carly Roleder, P. Sportelli, H. Miskin, Lu Chen, T. Phillips, Alexey V. Danilov   +9 more
semanticscholar   +1 more source

Abstract 4366329: Comparative Cardiovascular Outcomes in Acalabrutinib vs Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study

Circulation
Background: Next-generation Bruton’s tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and ...
Maan Awad, Het Patel, Prajwal Kumsi Sreedhar, S. Lingamsetty, Abdulrahman Murshid, Brijesh Patel   +5 more
semanticscholar   +1 more source

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Lancet Oncology, The, 2021
Matthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva   +2 more
exaly  

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

Leukemia, 2021
Hernando Yesid Estupiñán Velásquez, Gerard C P Schaafsma, Dara K Mohammad   +2 more
exaly  

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

Leukemia, 2021
Susan M O'brien, Jennifer R Brown, Peter Hillmen   +2 more
exaly  

Acalabrutinib (Calquence)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant (ASCT) in combination with bendamustine and rituximab (BR), if certain conditions are met.
openaire   +1 more source